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Abstract 
Factor VIII (fVIII) is a procoagulant protein that binds to activated factor IX (fIXa) on platelet surfaces to 
form the intrinsic tenase complex. Due to the high immunogenicity of fVIII, generation of antibody 
inhibitors is a common occurrence in patients during hemophilia A treatment and spontaneously occurs 
in acquired hemophilia A patients. Non-classical antibody inhibitors, which block fVIII activation by 
thrombin and formation of the tenase complex, are the most common anti-C2 domain pathogenic 
inhibitors in hemophilia A murine models and have been identified in patient plasmas. In this study, we 
report on the X-ray crystal structure of a B domain-deleted bioengineered fVIII bound to the non-classical 
antibody inhibitor, G99. While binding to G99 does not disrupt the overall domain architecture of fVIII, 
the C2 domain undergoes an ~8 Å translocation that is concomitant with breaking multiple domain-
domain interactions. Analysis of normalized B-factor values revealed several solvent-exposed loops in 
the C1 and C2 domains which experience a decrease in thermal motion in the presence of inhibitory 
antibodies. Our results enhance our understanding on the structural nature of binding non-classical 
inhibitors and provide a structural dynamics-based rationale for cooperativity between anti-C domain 
inhibitors.  
Introduction 
Hemophilia A is an X-linked recessive disorder caused by mutation to the F8 gene which results in a 
deficiency of coagulation factor VIII (fVIII), where severe mutations abolish fVIII production completely. 
Patients with hemophilia A are prone to uncontrolled bleeding events and require regular infusions of 
recombinant or plasma-derived fVIII to maintain functional coagulation (1,2). In approximately 30% of 
hemophilia A treatment cases, patients will produce antibodies that inhibit infused fVIII and reduce 
treatment efficacy (3,4). Furthermore, acquired hemophilia A can develop in healthy individuals through 
an autoimmune response, producing antibody inhibitors which bind to and inhibit the cofactor activity 
of native fVIII (5). Immune tolerance induction has been demonstrated to overwhelm the immune 
system through frequent, high-dosages of fVIII with modest success (3), but can be a physical and 
financial burden for the patient (6). 
 
Coagulation fVIII is a multidomain glycoprotein that circulates in the bloodstream as a heterodimer of 
the heavy chain (A1-A2) and light chain (A3-C1-C2) while bound to von Willebrand factor (vWf) to 
prevent premature clearance and/or degradation (2,7). Once cleaved by thrombin, activated fVIII (fVIIIa) 
dissociates from vWf and binds activated platelet surfaces, likely through embedding several solvent-
exposed hydrophobic loops on the C1 and C2 domains (8–10). Binding to activated factor IX (fIXa), a 
serine protease, forms the ‘intrinsic’ tenase complex which amplifies the generation of activated factor 
X (fXa) and subsequently thrombin. 
 
One example of a fVIII replacement therapeutic is ET3i, a bioengineered human-porcine chimera of B-
domain deleted fVIII. ET3i consists of porcine A1 and A3 domains and human A2, C1, and C2 domains. 
Domain swapping was employed to increase protein expression and stability, while still maintaining 
function (11,12). Additionally, ET3i undergoes slower A2 dissociation upon activation by thrombin, 
prolonging half-life (13).  
 
Previous studies indicate the A2, C1, and C2 domains to be highly immunogenic, where C2 is 
immunodominant (4,14–17). Anti-C2 domain inhibitors represent a diverse group of fVIII neutralizing 
antibodies and are categorized as classical and non-classical antibodies (18–20). Classical antibodies 
inhibit fVIII binding to vWf and platelet surfaces and their associated epitopes are categorized into 
groups A, AB or B (18). X-ray crystal structures of the isolated C2 domain bound classical inhibitors such 
as BO2C11 (21) and 3E6 (22,23) have identified unique conformational epitopes and demonstrated how 
inhibitor binding reduces circulatory levels of fVIII. Conversely, non-classical antibodies prevent fVIII 
activation by thrombin or fXa and their epitopes are categorized into groups BC and C (18). Non-classical 
antibodies are the most common pathogenic inhibitors in hemophilia A murine models (18) and 
inhibitors with overlapping epitopes have been detected in hemophilia A patient plasma (19). Group BC 
inhibitors are the most common anti-C2 antibodies and display above-average titer levels, particularly 
in patients with acquired hemophilia A (18), representing a significant clinical complication. In the 
presence of non-classical inhibitors, the binding of classical inhibitors to fVIII has been shown to increase 
(24). Additionally, hydrogen-deuterium exchange (HDX) protection patterns suggest cooperativity 
between anti-fVIII inhibitors, G99 and 3E6 (25). 
The pathogenic, non-classical antibody inhibitor G99 is a group BC inhibitor and binds to several solvent-
exposed loops in the C2 domain that are predicted to interact with thrombin and fIXa (26,27).. Epitope 
mapping based on HDX rates indicate residues 2200-2228 are a major determinant in G99 binding (28), 
including K2227 which, upon substitution with glutamic acid, abrogates fVIII binding to G99 (18). The 
crystal structure of the isolated C2 domain bound to G99 identified a conformational epitope composed 
of multiple loops and revealed K2227 forms multiple electrostatic contacts with the G99 light chain (22). 
Here, we present the crystal structure of ET3i (29–31) bound to the G99 antigen binding fragment (FAB). 
Our structure represents the first crystal structure of a fVIII replacement therapeutic bound to an anti-
C2 inhibitor, providing insight into how non-classical inhibitors alter the C2 domain conformation of 
mature fVIII and allosterically influence the thermal motion of nearby epitopes. 
Materials and Methods 
Expression and Purification of ET3i 
ET3i was expressed and purified as previously described (29,30) to a final concentration of 0.8 mg/mL 
and stored in 50 mM HEPES, pH 7.4, 5 mM CaCl2 and 350 mM NaCl at -80 °C. 
Purification of G99 FAB Fragments 
G99 monoclonal antibodies were expressed and purified in hybridoma cell lines and FAB fragments were 
prepared as previously described (18,22). Briefly, large-scale antibody production was performed at the 
Antibody Production Facility at the Fred Hutch (Seattle, WA). Immunoglobulin (IgG) and FAB purifications 
were completed with Protein A Plus spin columns and immobilized papain kits (Thermo Scientific, 
Rockford, IL) according to the manufacturer’s protocols. Purified FAB fragments were stored at a final 
concentration of 10 mg/mL at -80 °C in FAB storage buffer (25 mM Tris-HCl pH 7.2, 100 mM NaCl).  
Crystallization, Data Collection, and Refinement 
The ET3i:G99 FAB complex was formed at a 1:1.2 stoichiometric ratio in 50 mM Tris HCl (pH 7.4), 200 mM 
NaCl, and 2.5 mM CaCl2 and purified using a 100 kDa MWCO spin column (Amicon) to 1 mg/mL. Initial 
crystal conditions were determined via high-throughput microbatch crystallization using the Hauptman-
Woodward High-Throughput Crystallization Center (Buffalo, NY) (27). Diffraction quality crystals were 
subsequently grown by hanging drop vapor diffusion in a 1:1 (v/v) ratio of the ET3i:G99 protein complex 
and crystallization solution containing 50 mM malic acid (pH 7.0) and 8-18% (w/v) PEG 1500, PEG 6000, 
or PEG 10,000. Crystals were cryoprotected in mother liquor with the stepwise addition of 30% (v/v) 
glycerol. X-ray diffraction data were collected on the Advanced Light Source (ALS) Berkeley Center for 
Structural Biology (BCSB) beamline 5.0.1 (Berkeley, CA). Data collection and processing were performed 
with Adxv, XDS and CCP4 (32).. Phasing of the ET3i:G99 crystals was determined with PHASER-MR using 
a fragment-based molecular replacement approach with the previously determined 3.2 Å structure of 
ET3i (PDB ID: 6MF0) and the 2.47 Å structure of human factor VIII C2 domain in complex with murine 
inhibitory antibodies 3E6 and G99 (PDB ID: 4KI5) (22,31,33). Model building and refinement were 
performed with WinCoot and PHENIX, respectively (34). All figures were generated with the PyMOL 
Molecular Graphics System, Version 2.0 (Schrödinger, LLC).  
Results 
Crystal Structure of Factor VIII in Complex with the Anti-C2 Domain G99 Antibody 
The X-ray crystal structure of the ET3i B domain-deleted fVIII construct bound to G99 was determined at 
4.15 Å resolution and refined to Rwork/Rfree values of 0.2998/0.3384 (PDB ID: 7KBT) (Figure 1A, Table S1). 
The asymmetric unit (ASU) contains one molecule consisting of the A1, A2, A3, C1, and C2 domains of 
ET3i and the variable domains of the heavy and light chains of G99. While the FAB constant domains were 
included in the protein complex, these domains could not be modeled into the final structure, 
presumably due to flexibility, and thus were excluded. The ET3i:G99 complex superimposes well with 
the crystal structure of the isolated C2 domain bound to G99 (PDB ID: 4KI5) (22) with a root-mean-square 
deviation (RMSD) value of 0.81 Å2 (Figure 1B). Both complexes have structurally identical epitopes for 
the G99 inhibitor antibody which encompass residues 2193-2194, 2222-2229, 2161-2163, 2269-2282, 
and 2307-2311 (Figure 1C).  The nature of the C2/G99 binding interface relies on a combination of polar 
and hydrophobic interactions. Figure 1D illustrates how K2227 is a critical residue for binding to G99, 
participating in multiple electrostatic interactions with E50, T99, and Y96. The epitope spanning residues 
2222-2229 provides multiple points of contact with the heavy chain of G99 (Figure 1E), including E2228 
which has been proposed to interact with the Gla domain of fIXa (27). Lastly, residues L2261, L2273, 
V2280, and V2282, previously suggested as a binding site for thrombin (26), form direct, extensive 
contacts with the G99 light chain (Figure 1F). Our structure of ET3i bound to the G99 FAB fragment 
illustrates how non-classical inhibitors potentially block the binding of thrombin, fXa and fIXa, thus 
preventing dissociation from vWf and formation of the tenase complex.  
Binding G99 Induces a Conformational Rearrangement to the C2 Domain in Mature Factor VIII 
Alignment of the ET3i:G99 complex to the unbound ET3i structure (PDB ID: 6MF0) (31) suggests that 
binding G99 does not disrupt the overall ET3i structure, with an average RMSD of 0.68 Å2 (Figure 2A). 
Figure 1. Crystal structure of ET3i bound to the G99 FAB fragment. (A) Cartoon representation of the B domain deleted 
bioengineered fVIII construct (ET3i) bound to the variable domain of G99 inhibitor antibody. Porcine A1 and A3 (pA1 and 
pA3) domains are colored dark red and pink, respectively, and human A2, C1, and C2 (hA2, hC1, and hC2) domains are 
colored cyan. Heavy and light chains of the G99 FAB fragment (G99HC and G99LC) are colored green and purple, respectively. 
N-acetylglucosamine modifications are depicted as sticks. (B) Ribbon diagram of aligned C2 domain (cyan) and G99 heavy 
and light chains (green and purple, respectively) from the ET3i:G99 crystal structure and of the isolated C2 domain bound 
to G99 (grey; PDB ID: 4KI5) in stereo view. (C) Stick representation of the G99 epitope from the ET3i:G99 (cyan) and C2:G99 
(grey, faded) crystal structures. (D,E) Electrostatic contacts between ET3i epitope 2222-2229 (cyan) and G99 heavy chain 
(green) and light chain (purple). Dotted lines depict hydrogen bonds (distance ≤ 5 Å). (F) Hydrophobic residues along the 
ET3i epitope 2269-2282 (cyan) buried by the G99 light chain (purple). 
 
The C2 domain, however, shows the largest 
conformational change upon binding G99 (Figures 
2B, 2C), undergoing an ~8 Å translocation relative 
to the other ET3i domains. Most of these 
conformational changes are localized to several 
loops proximal to the G99 epitope, including 
residues 2256-2265, 2270-2285, and 2305-2314. 
This rearrangement to the C2 domain is 
concomitant with breaking multiple interfacial 
contacts with the adjacent A1 and C1 domains 
(Figure 2A). The A1/C2 interface includes 
interactions between amino acids E123, N2172, 
and K2239 that are disrupted due to K2239 
shifting by 5 Å in the ET3i:G99 structure. The 
C1/C2 interface includes interactions between 
amino acids H2031 and S2296, and D2170 and 
S2175, both of which become disrupted in the 
ET3i:G99 complex. Lastly, the ET3i:G99 crystal 
structure reveals loss of an intramolecular contact 
within the C2 domain between R2304 and Q2266. 
While the extent of disruption to these 
interactions is not definitive given the lower 
resolution of the crystallographic data, the 
structure of ET3i:G99 does show significant 
rearrangement to the C2 domain with the greatest 
conformational changes occurring to the 
aforementioned regions. 
Analysis of B-Factor Values from Multiple ET3i 
Crystal Structures 
To further investigate how inhibitor binding 
influences the flexibility of C domain epitopes, we 
performed a comparative B-factor analysis on the 
C1 and C2 domains from several crystal structures 
of ET3i bound to antibody inhibitors as well as the 
unbound ET3i structure (Figures 3A, 3B). B-factor 
values are calculated by the spatial fluctuation of 
atoms in a crystal structure from their equilibrium 
positions (35) and provide insight into protein 
structure thermostability, with low values indicating rigidity and high values indicating flexibility (units, 
Å2). In addition to the unbound ET3i and ET3i:G99 crystal structures, we also included the crystal 
structure of ET3i complexed with the anti-C1 domain inhibitor 2A9 (PDB ID: 7K66) in our analysis as the 
C2 domain in this structure undergoes a similar translocation (36). To better compare between each 
Figure 2. Structural alignment of unbound ET3i and 
ET3i:G99 crystal structures. (A) Alignment of unbound ET3i 
(grey) and ET3i:G99 (A1: dark red, A3: pink, A2/C1/C2: cyan). 
Insets depict intramolecular contacts that are broken in the 
ET3i:G99 structure. (B) Alignment of the C2 domain from 
unbound ET3i structure (grey) and ET3i:G99 structure (cyan). 
(C) Structure of the C2 domain from the ET3i:G99 complex 
colored as a function of RMSD from alignment with unbound 
ET3i. White: low RMSD shifts, orange: large RMSD shifts.  
 




                                                     (1) 
where B is the raw atomic B-factor, Baverage is the average B-factor of the ET3i molecule in the crystal 
asymmetric unit, and Resolution is the reported atomic resolution for the respective structure. Model A 
of the unbound ET3i crystal structure, which has two ET3i molecules in the ASU (31), was used to 
compare with the antibody-bound structures. 
 
The average B’ values at known C1 and C2 
domain epitopes (Figure 3C) from three 
ET3i crystal structures were tabulated for 
comparison (Table 1). As expected, regions 
that experience some of the greatest 
decreases in B’ values occur directly at the 
epitopes from the antibody-bound 
structures. Residues 2065-2070, 2110-
2112, and 2150-2156 in the ET3i:2A9 
structure, which encompass the 2A9 
epitope, have 35.2%, 27.2%, and 26.1% 
lower B’ values, respectively, compared to 
the free ET3i structure (Figure S1). Similarly, 
residues 2269-2282, which form extensive 
interactions with the G99 antibody, have a 
37.9% lower average B’ value in the 
ET3i:G99 complex than the unbound ET3i 
structure (Figure S2). These observed 
differences in B’ values are due to the 
inhibitory antibody binding to the 
respective epitope and reducing atomic 
motions. 
 
Previous work focusing on the atomic B-
factors from crystal structures of the 
isolated C2 domain bound to classical and 
non-classical inhibitory antibodies 
identified fluctuations to the thermostability 
in certain epitopes  (17,23).  We sought to 
expand our understanding on this topic by 
calculating the B’ values in the C1 and C2 
domain epitopes when the opposing 
domain was bound to an inhibitory 
antibody. Our results indicate that antibody 
binding is a potent allosteric modulator of 
Figure 3. Anti-C domain inhibitors reduce atomic B-factors on 
solvent-exposed loops. (A,B) Normalized atomic B-factors averaged 
for each epitope in the (A) C1 domain and (B) C2 domain from 
unbound ET3i (black, PDB ID: 6MF0), ET3i:G99 (blue, PDB ID: 7KBT), 
and ET3i:2A9 (red, PDB ID: 7K66). (C) Cartoon representation of the 
C1 and C2 domains from the unbound ET3i crystal structure (PDB ID: 
6MF0, model A). Antibody epitopes are highlighted (2A9: magenta, 
G99: green, 3E6: cyan, BO2C11: orange). 
 
atomic motions to adjacent epitope (Table 1). For instance, residues 2269-2282, which participate in 
binding G99 to the C2 domain, have a 24.4% lower average B’ value in the ET3i:2A9 structure than the 
unbound ET3i structure. Similarly, B’ values from residues that comprise the 2A9 epitope in the ET3i:G99 
crystal structure are lower than the unbound ET3i structure, most notably residues 2065-2070 which 
have a 23.5% lower average B’ value. By calculating the average B’ value for each amino acid at these 
epitopes, we determined that P2067 and F2068 of residues 2065-2070 and Q2276, N2277, and G2278 
of residues 2069-2282 experience the greatest reduction in atomic motions (Figures S1 and S2). None of 
the aforementioned “coldspots” participate in lattice contacts within the protein crystal, indicating an 
alternate mechanism for reducing peptide flexibility. While differences in B’ values can be due to 
variables that are unaccounted for in equation 1, such as crystallization conditions or refinement 
strategy, these results are indicative of an allosteric relationship between anti-C1 and anti-C2 epitopes 
in the presence of inhibitor antibodies.  
 ET3i ET3i:G99 ET3i:2A9 
A1-A2/A3-C1-C2 0.307 0.241 (-21.5%) 0.255 (-16.9%) 
2A9 epitope    
2065-2070 0.322 0.247 (-23.5%) 0.209 (-35.2%) 
2110-2112 0.352 0.235 (-33.1%) 0.256 (-27.2%) 
2150-2156 0.260 0.218 (-16.4%) 0.192 (-26.1%) 
G99 epitope    
2193-2194 0.319 0.264 (-17.5%) 0.279 (-12.6%) 
2222-2229 0.323 0.263 (-18.4%) 0.284 (-12.0%) 
2261-2263 0.294 0.241 (-18.0%) 0.260 (-11.5%) 
2269-2282 0.422 0.262 (-37.9%) 0.319 (-24.4%) 
2307-2311 0.286 0.239 (-16.3%) 0.266 (-7.1%) 
3E6 epitope    
2181-2188 0.311 0.257 (-17.4%) 0.293 (-5.9%) 
2202-2215 0.326 0.269 (-17.5%) 0.267 (-18.3%) 
BO2C11 epitope    
2195-2202 0.404 0.291 (-28.0%) 0.339 (-16.0%) 
2247-2255 0.337 0.251 (-25.5%) 0.270 (-19.9%) 
 
We next investigated the atomic thermostability for residues spanning the epitopes for 3E6 and BO2C11 
antibodies, which bind to unique regions on the C2 domain (Figure 3C) and are categorized as classical 
inhibitors (21–23), in the ET3i:G99 and ET3i:2A9 crystal structures. We measured reduced B’ values for 
the 3E6 epitope in the ET3i:2A9 and ET3i:G99 structures when compared with the unbound ET3i 
structure. Specifically, the 3E6 epitope spanning residues 2202-2215 had an 18% lower average B’ in 
Table 1. Average B’ values for C1 and C2 domain epitopes. Values in parentheses depict percent differences from 
the unbound ET3i structure. Bold values represent differences that are greater than the average ET3i molecule 
(“coldspots”). 
both inhibitor-bound crystal structures (Table 1, Figure S3). Residues 2195-2202 and 2247-2255, which 
encompass the BO2C11 epitope (21), have 16% and 19.9% lower B’ values in the ET3i:2A9 crystal 
structure, respectively, and are even lower in the ET3i:G99 structure (28.0% and 25.5%, respectively) 
(Table 1, Figure S4). Taken together, these results support the hypothesis that these regions on the C2 
domain become more rigid when bound to either G99 or 2A9.  
Discussion 
In this study, we report on the crystal structure of ET3i, a bioengineered fVIII molecule, bound to the 
pathogenic, non-classical antibody inhibitor G99. While the A domains are structurally unperturbed by 
G99 binding, the C2 domain undergoes an ~8 Å translocation and loses multiple intramolecular contacts 
with the adjacent A1 and C1 domains. Mutations at the A1/C2 and C1/C2 domain interfaces have been 
identified in multiple hemophilia A cases, including E123K, K2239E, and R2304L/G/C (37–40). 
Considering the crystal structure of ET3i:G99 indicates binding to G99 disrupts these domain-domain 
contacts, we speculate how mutations to these regions influence the C2 domain conformation and 
inhibitor binding. In a previous surface plasmon resonance-based study with a suite of fVIII point 
mutants, researchers mapped the epitopes of 11 anti-C2 antibody inhibitors and identified several 
residues that are not part of a contiguous epitope, yet significantly impact binding to anti-C2 inhibitors 
when mutated (41). K2239, which participates in multiple hydrogen bonds at the A1/C2 domain interface 
(Figure 2A), demonstrated slightly stronger binding with the classical antibody 3E6 when substituted 
with alanine. Furthermore, R2304C, which is linked to moderate cases of hemophilia A and high inhibitor 
titer levels (38,40), has been proposed to destabilize fVIII without disrupting vWf and phospholipid 
binding (42). These data are indicative of a unique relationship between C2 domain-domain contacts and 
fVIII immunogenicity. Disruption to domain interfacial contacts may induce a structural rearrangement 
to the C2 domain and enhance immune recognition and inhibitor binding. Our structure of the ET3i:G99 
complex provides evidence for a connection between disruption to domain-domain contacts near the 
C2 domain and inhibitor binding. 
 
Normalization and comparison of B-factors between different crystal structures has previously been 
utilized to study the effects of ligand binding (43), mutagenesis (44), environmental pH (45), as well as 
protein engineering to enhance stability (46). Our analysis of normalized B-factors from several ET3i 
structures in the absence and presence of inhibitor antibodies suggests that binding G99 induces 
structural rigidity in multiple solvent-exposed regions of the C domains that are not a part of the G99 
epitope. HDX protection patterns have been identified for residues 2231-2252 using the isolated C2 
domain bound to G99 (28). Our results support these findings, with the greatest reduction in atomic 
motions occurring to residues 2249-2252 at both the amino acid functional group and the peptide 
backbone (Figure S2). 
 
Adjustments to the thermostability in certain fVIII epitopes raise important questions regarding immune 
recognition and cooperativity between classical and non-classical anti-C2 domain inhibitors. Indeed, 
synthetic peptides encompassing the G99 epitope have been shown to stimulate CD4+ T-cell 
proliferation and induce an immune response, including residues 2301-2320 which had the strongest 
response among acquired hemophilia A patients (17). Because the degree of peptide flexibility is a strong 
determinant in T-cell recognition and binding to T-cell receptors (47–49), reducing the dynamic mobility 
in certain fVIII epitopes is a potential mechanism in fVIII immune recognition. Furthermore, group A 
classical inhibitors have elevated association rates with fVIII when in the presence of non-classical group 
BC antibodies (24,50), providing evidence for a cooperative immune response to fVIII. HDX 
measurements on the isolated C2 domain pre-mixed with G99 and 3E6 had stronger protection patterns 
than the individually bound complexes (25). Structural characterization of the C2 domain bound to G99 
and 3E6 FAB fragments supports a polyclonal response to fVIII (22,51). Our analysis of normalized B-
factors suggests that cooperativity between inhibitors relies on reducing local disorder to these regions. 
Lowering atomic motions may reduce the conformational diversity of certain epitopes, thereby 
decreasing the entropic cost in macromolecular association, to provide a high-affinity binding site for 
antibody inhibitors (23,52,53). Modification of these epitopes to prevent rigidification and promote 
conformational diversity may present a novel strategy in the design of fVIII replacement therapeutics 
with reduced immunogenicity. 
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Table S1.  X-ray data collection and refinement statistics. 
 
Wavelength (Å) 1 
Resolution range (Å) 25.48  - 4.15 (4.298  - 4.15) 
Space group P 41 21 2 
Unit cell a = 132.243, b = 132.243, c = 380.029; α, β, γ = 90° 
Total reflections 52,566 (50,92) 
Unique reflections 26,284 (2,546) 
Multiplicity 2.0 (2.0) 
Completeness (%) 99.08 (98.31) 
Mean I/sigma(I) 6.31 (0.48) 
Wilson B-factor 195.91 
Rmerge 0.06373 (1.359) 
Rmeas 0.09012 (1.922) 
Rpim 0.06373 (1.359) 
CC1/2 0.998 (0.373) 
CC* 1 (0.737) 
Reflections used in refinement 26,198 (2,504) 
Reflections used for Rfree 1,987 (191) 
Rwork 0.2998 (0.4645) 
Rfree 0.3384 (0.4481) 
Number of non-hydrogen atoms 11,366 
  macromolecules 11,293 
  ligands 73 
Protein residues 1,444 
RMS (bonds) 0.005 
RMS (angles) 1.07 
Ramachandran favored (%) 78.02 
Ramachandran allowed (%) 15.15 
Ramachandran outliers (%) 6.83 
Rotamer outliers (%) 0.08 
Clashscore 15.7 
Average B-factor 253.38 
  macromolecules 253.25 




Supplementary Figure 1. Atomic B’ values per amino acid for 2A9 epitope. (Left) Cartoon structure of the 
C1 domain highlighting 2A9 epitope (magenta). (Right) Solid circles represent the average B’ of the amino 
acids and faded circles represent the B’ value of the Cα atoms from unbound ET3i (black, PDB ID: 6MF0), 
ET3i:G99 (blue, PDB ID: 7KBT), and ET3i:2A9 (red, PDB ID: 7K66).  
Supplementary Figure 2. Atomic B’ values per amino acid for G99 epitope. (Left) Cartoon structure of the 
C2 domain highlighting G99 epitope (green). (Right) Solid circles represent the average B’ of the amino acids 
and faded circles represent the B’ value of the Cα atoms from unbound ET3i (black, PDB ID: 6MF0), ET3i:G99 
(blue, PDB ID: 7KBT), and ET3i:2A9 (red, PDB ID: 7K66).  
 
 
Supplementary Figure 3. Atomic B’ values per amino acid for 3E6 epitope. (Left) Cartoon structure of the 
C2 domain highlighting 3E6 epitope (cyan). (Right) Solid circles represent the average B’ of the amino acids 
and faded circles represent the B’ value of the Cα atoms from unbound ET3i (black, PDB ID: 6MF0), ET3i:G99 
(blue, PDB ID: 7KBT), and ET3i:2A9 (red, PDB ID: 7K66).  
 
Supplementary Figure 4. Atomic B’ values per amino acid for BO2C11 epitope. (Left) Cartoon structure of 
the C2 domain highlighting BO2C11 epitope (orange). (Right) Solid circles represent the average B’ of the 
amino acids and faded circles represent the B’ value of the Cα atoms from unbound ET3i (black, PDB ID: 
6MF0), ET3i:G99 (blue, PDB ID: 7KBT), and ET3i:2A9 (red, PDB ID: 7K66).  
 
